Product Pipeline

 

Innovative, exciting technology with extraordinary potential

Our pipeline currently centers on two promising compounds developed by world renowned Professors’ Chang and Han.

This platform drug as shown promise for the treatment of Acute Myeloid Leukemia.  Formally known as TPA, this platform small molecule has many potential therapeutic uses.  Rich Pharmaceuticals is exploring multiple indications for the highest likelihood of commercialization success that has the potential to become new compelling treatments for patients.

News

April 10th, 2018

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
View Release

March 14th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
View Release

March 6th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
View Release

» View All News

Stock Price